Corporate News     28-Jul-17
Astrazeneca Pharma India intimates of delay on termination of distribution arrangements for Menorem in India
Due to delay in divestment of AstraZeneca's global rights to Meronem
Astrazeneca Pharma India announced that it has received a letter from AstraZeneca UK to further extend the date of withdrawal of Meronem from 31 July 2017 to 31 August 2017, due to delay in the divestment of AstraZeneca's global rights to Meronem.

In August 2016, Astrazeneca had announced the termination of distribution arrangement by AstraZeneca UK for Meronem in India, pursuant to a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc., of its late stage small molecule antibiotics business.

Further in December 2016, the validity period of the distribution agreement was extended till 31 July 2017, due to delay in the divestment of AstraZeneca's global rights to Meronem.

Previous News
  Astrazeneca Pharma India standalone net profit rises 2.57% in the March 2022 quarter
 ( Results - Announcements 27-May-22   08:06 )
  AstraZeneca Pharma, Mankind Pharma partner to accelerate access to asthma medicine
 ( Hot Pursuit - 12-Mar-24   13:02 )
  Astrazeneca Pharma India schedules board meeting
 ( Corporate News - 25-May-23   15:01 )
  AstraZeneca India gets govt nod for import & sale of cancer-treating drug Enhertu
 ( Hot Pursuit - 04-May-23   11:28 )
  Astrazeneca Pharma India standalone net profit declines 2.44% in the March 2020 quarter
 ( Results - Announcements 18-May-20   18:30 )
  Astrazeneca Pharma India to hold board meeting
 ( Corporate News - 22-Jan-20   10:30 )
  AstraZeneca Pharma India appoints director
 ( Corporate News - 13-Aug-20   10:21 )
  Astrazeneca Pharma India AGM scheduled
 ( Corporate News - 27-May-21   14:24 )
  Astrazeneca Pharma India standalone net profit rises 288.60% in the June 2016 quarter
 ( Results - Announcements 10-Aug-16   11:47 )
  Astrazeneca Pharma India to announce Quarterly Result
 ( Corporate News - 24-Oct-20   10:03 )
  Astrazeneca tumbles after Q4 PAT slides 2.4% to Rs 9.58 cr
 ( Hot Pursuit - 19-May-20   11:16 )
Other Stories
  Board of Delhivery approves alteration in capital clause of MoA
  05-Jul-24   19:32
  J B Chemicals & Pharmaceuticals appoints director
  05-Jul-24   19:30
  Infosys announces resignation of senior management personnel
  05-Jul-24   19:22
  JLR Q1 FY25 retail sales up 9% on YoY basis
  05-Jul-24   19:08
  Bajaj Auto launches world's first CNG motorcycle 'Freedom'
  05-Jul-24   18:59
  Agenda for board meeting of Power Grid Corporation of India
  05-Jul-24   18:46
  Board of Bank of Baroda approves raising additional capital up to Rs 7,500 cr in FY25
  05-Jul-24   18:06
  Vipul to hold board meeting
  05-Jul-24   17:15
  Markobenz Ventures to convene board meeting
  05-Jul-24   17:15
  Dhanashree Electronics to declare Quarterly Result
  05-Jul-24   17:15
Back Top